Ask AI

Experts Discuss Optimizing Quadruplet Therapy in Newly Diagnosed Multiple Myeloma

Clinical Thought
Clinical Thought Start Activity
This activity is available for 0.25 CME/CE credit(s).

Released: October 19, 2026

Expiration: April 18, 2027

See Activity Collection

In this commentary, expert faculty discuss the evolving role of quadruplet therapy in newly diagnosed multiple myeloma, with emphasis on treatment selection across transplant-eligible and transplant-ineligible populations, incorporation of anti-CD38 antibodies and proteasome inhibitors, and tailoring treatment intensity according to disease risk, fitness, and response. The faculty examine phase III and other clinical data informing contemporary frontline treatment and address unresolved questions regarding the optimal use and duration of bortezomib, the role of autologous stem cell transplantation in the quadruplet era, and the use of MRD status to inform treatment decisions. Maintenance strategies with lenalidomide alone or in combination with anti-CD38 therapy are also discussed. 

NDMM Quadruplet Therapy

Pre Assessment

Assess your current knowledge and clinical approach before beginning your ClinicalThought.
1.

How many people with multiple myeloma do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

Which statement best reflects the current role of ASCT for transplant-eligible patients receiving contemporary quadruplet therapy for NDMM?

4.

A patient with newly diagnosed standard-risk multiple myeloma is treated with anti-CD38 antibody-based quadruplet therapy induction/consolidation and transplant, achieving an sCR but not reaching MRD negativity. The patient starts maintenance therapy with an anti-CD38 antibody plus lenalidomide. How long would you plan to continue anti-CD38 antibody maintenance therapy based on current evidence and expert recommendations, provided the patient achieves MRD negativity?